热点回应丨超4万批文面临出清考验 中药即将告别“尚不明确〞

Core Viewpoint - The new regulation from the National Medical Products Administration (NMPA) will eliminate ambiguous safety information in traditional Chinese medicine (TCM) product labels, significantly impacting over 70% of existing TCM approvals by 2026 [1][2]. Group 1: Background and Purpose of the Regulation - The regulation aims to address the safety information gaps in TCM product labels, promoting high-quality development in the TCM industry [2]. - Approximately 57,000 TCM approvals exist in China, with over 40,000 labels indicating "not clear" for contraindications, adverse reactions, or precautions [2]. - The regulation will primarily affect TCM products with unclear clinical value and high safety risks, as well as traditional formulations lacking modern research data [2]. Group 2: Impact on Existing Products - Current TCM products in circulation, such as Ban Lan Gen and Lianhua Qingwen, will not be directly affected, allowing consumers to continue using them [3]. - The regulation applies to the re-registration process, meaning existing stock can still be sold legally [3]. - Leading companies like Yiling Pharmaceutical and Baiyunshan Pharmaceutical Group are proactively investing in post-market safety evaluations to meet the new standards [3]. Group 3: Industry Transformation - The regulation signifies a shift in the TCM industry from quantity expansion to quality prioritization, addressing issues of low clinical value and redundancy among TCM products [4]. - An estimated 20%-30% of TCM approvals may exit the market in the next 3-5 years due to the new standards [4]. Group 4: Cost Implications for Companies - Companies may face increased research costs for safety evaluations, typically ranging from hundreds of thousands to millions of yuan per product [6]. - However, this is not expected to lead to significant price increases for TCM products due to market competition and the potential for cost dilution through scale production [6]. - The top 100 TCM products account for over 60% of the market share, indicating that leading companies with solid research foundations can manage the costs effectively [6]. Group 5: Support Mechanisms - National and provincial drug regulatory authorities have established communication mechanisms and green channels to support companies in conducting necessary research and expedite the review of supplementary applications for urgently needed products [7].